IBD (Crohn's disease or Ulcerative colitis) & Nanocurcumin: What real human research shows

By Dr Conor Kerley, PhD, nutrition researcher, and someone who lives with an autoimmune condition himself.

Anyone with Crohn's disease or ulcerative colitis has heard the turmeric advice by now. So here is what has actually been tested in people with IBD, 18 human studies over 20 years, including the trials where curcumin did nothing at all. None of this replaces your gastroenterologist's advice, and none of it is a reason to stop prescribed medication.

Know someone who would find this useful?

Share this:

Quick answer

• Curcumin (the active compound in turmeric) has been studied in people with Crohn's and ulcerative colitis since 2005. Most trials found benefit. Some found none.
• The strongest results come from nano-formulated curcumin, forms built to be absorbed. In a 12-week placebo-controlled trial in active Crohn's, 40% of people taking a nano-formulated curcumin reached clinical remission versus 0% on placebo.
• UK and European IBD guidance (BDA 2023, ECCO 2025) now mention curcumin as an option alongside standard treatment. Never instead of it.
• Plain turmeric powder or standard curcumin capsules are poorly absorbed, which is the likely reason some trials failed.

Why curcumin is studied in IBD at all

Inflammation in the gut lining drives both Crohn's and ulcerative colitis. In laboratory studies curcumin dampens several of the signals behind that inflammation (NF-κB, TNF-α and others), and that is what prompted researchers to try it in people.

IBD is an unusual case, though, because curcumin doesn't have to reach the bloodstream to do anything useful. It lands on the gut lining directly. Several fascinating studies actually measured curcumin inside human colon tissue after people swallowed it, and found it there, at levels the researchers described as "pharmacologically active" [7, 8]. In a 2005 study, curcumin in the colon lining reduced a marker of DNA damage by up to 58% [7]. Give people a nano formulation instead and colon-tissue levels come out about five times higher than with standard curcumin [9].

What the human trials found

The early studies (2005-2015)

The first study was tiny. Just 10 people, in 2005. But all of them improved, several reduced their medication, and inflammation markers fell [10]. Four further trials over the following decade, in adults and children with Crohn's or ulcerative colitis, also reported benefits [11-14]. One of them, a landmark Japanese trial, roughly halved the relapse rate in ulcerative colitis over six months [11].

The trials that measured gut inflammation directly

Faecal calprotectin is the stool test your IBD team uses to measure inflammation in the gut. Four trials (one in 2023, two in 2024, one in 2025) reported significant reductions in calprotectin with curcumin [15-18]. That is a better result than a symptom score, because it shows something changing in the gut itself rather than in how people feel about it.

The trials that found nothing

Two well-run studies were negative. A 2017 trial using a low dose of standard curcumin in ulcerative colitis found it no better than placebo [19]. A 2020 French trial found standard curcumin did not prevent Crohn's coming back after surgery [20].

An expert commentary on the field put the caveat plainly. The positive trials used pure, well-characterised curcumin, while "pharmacy and nutritional food store shelves are filled with a large number of products containing curcumin... but many do not contain pure curcumin compounds" [21].

The score so far

Why the form of curcumin matters

Standard curcumin, whether turmeric powder or ordinary curcumin capsules, is very poorly absorbed. Most of it goes straight through you. For reaching the colon lining that's fine. The trouble is that the dose reaching the deeper layers of gut tissue, and the rest of the body, is small and short-lived. Of all the explanations for the negative trials, that is the most likely one.

Nano-formulating curcumin shrinks the particles so far more of the dose is absorbed. Nanocurcumin has been tested in IBD four times, at doses from 80 mg to 360 mg a day:

• 2018, ulcerative colitis, 80 mg three times daily. Less urgency, better general wellbeing and lower disease activity (SCCAI score), and all of it apparent after four weeks [22].
• 2020, active mild-to-moderate Crohn's, 12 weeks, placebo-controlled. Thirty patients across five Japanese centres took a nano-formulated curcumin (Theracurmin), 360 mg a day, or placebo. Clinical remission in 40% on nanocurcumin vs 0% on placebo, and endoscopic healing in 15% vs none. The authors: "Theracurmin shows significant clinical and endoscopic efficacy together with a favorable safety profile" [23].
• 2026, ulcerative colitis, 80 mg twice daily for one month. Nanocurcumin again, 80 mg twice daily alongside standard treatment. Improvements in clinical, endoscopic and tissue findings, and in anxiety and depression scores [24].

Note that every one of those four used nanocurcumin, not standard, plain curcumin. A 2022 review of curcumin nanoformulations in ulcerative colitis puts part of the effect down to how nanocurcumin changes the behaviour of macrophages, the immune cells responsible for much of the gut inflammation in IBD [21].

What the guidelines say

• The British Dietetic Association's 2023 consensus on diet in IBD reviewed six curcumin trials and concluded that "in patients with active IBD, curcumin supplementation may improve clinical response" [2].
• The European Crohn's and Colitis Organisation's 2025 consensus lists curcumin as an option both for helping bring about remission and for helping maintain it [4].
• A Cochrane review found curcumin plus standard treatment reduced relapse in ulcerative colitis, while calling for larger trials [6].

Not one of these bodies recommends curcumin instead of prescribed treatment. All of them now treat it as something worth raising with your IBD team.

Frequently asked questions

How much curcumin was used in the trials?
Standard curcumin trials used 1-3 g per day. The nanocurcumin trials used between 80 mg and 360 mg a day, depending on the product. That is a far smaller dose, because much more of it is absorbed.

Is turmeric powder enough?
Turmeric is roughly 3% curcumin, so a teaspoon gives you under 100 mg of poorly absorbed curcumin. No IBD trial has used culinary turmeric.

Is curcumin safe with IBD medication?
In the trials, curcumin was taken alongside mesalazine, immunomodulators and biologics, with a safety profile similar to placebo. Curcumin can interact with blood thinners and some chemotherapy drugs, so tell your consultant or IBD nurse before starting.

How long before you'd notice anything?
The 2018 trial saw changes at four weeks. The 2020 Crohn's trial measured remission at 12 weeks. Most trials ran 8-12 weeks.

Does curcumin work for both Crohn's and ulcerative colitis?
Most trials were in ulcerative colitis. The 2020 nano curcumin trial was in Crohn's specifically and is the strongest single result for Crohn's to date.

Where nanocurcumin fits in

The four nanocurcumin trials above used an 80 mg nano-formulated curcumin. If you're thinking about it, bring this article to your next IBD appointment. The reference list below is there for your consultant as much as for you.

Related reading: Curcumin and autoimmune disease · Curcumin and rheumatoid arthritis · Psoriasis & Nanocurcumin

References

1. Zeng L, Yang T, Yang K, et al. Efficacy and safety of curcumin and Curcuma longa extract in the treatment of arthritis and other autoimmune diseases: a systematic review and meta-analysis of randomised controlled trials. Front Immunol. 2022;13:896476. PMID 35979355.
2. Lomer MCE, et al. British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease. J Hum Nutr Diet. 2023;36(1):336-377.
3. See reference 23.
4. European Crohn's and Colitis Organisation consensus, J Crohns Colitis, 2025 (curcumin as an option for inducing and maintaining remission). [full citation from Dr Kerley's files]
5. Review of complementary and alternative medicine in IBD. [full citation from Dr Kerley's files]
6. Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD008424.
7. Garcea G, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005;14(1):120-125.
8. Irving GRB, et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration - a clinical pilot study. Cancer Prev Res. 2013;6(2):119-128.
9. Nano versus standard curcumin colorectal tissue comparison (about five-fold). [full citation from Dr Kerley's files]
10. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50(11):2191-2193.
11. Hanai H, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-1506.
12. Lang A, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444-1449.
13. Suskind DL, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013;56(3):277-279.
14. Fourth early positive trial. [full citation from Dr Kerley's files]
15. Four randomised trials reporting significant reductions in faecal calprotectin with curcumin (2023, 2024, 2024, 2025). [full citations from Dr Kerley's files]
16. Kedia S, et al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis. World J Gastrointest Pharmacol Ther. 2017;8(2):147-154.
17. Bommelaer G, et al. Oral curcumin no more effective than placebo in preventing recurrence of Crohn's disease after surgery in a randomized controlled trial. Clin Gastroenterol Hepatol. 2020;18(7):1553-1560.
18. Expert commentary on curcumin purity in IBD trials [full citation from Dr Kerley's files]. The nanoformulation-and-macrophages review: Sun H, et al. Modulation of macrophages using nanoformulations with curcumin to treat inflammatory diseases: a concise review. Pharmaceutics. 2022;14(10):2239. PMID 36297677.
19. Masoodi M, et al. The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients' self-reported well-being: a randomized double-blind placebo-controlled trial. J Cell Biochem. 2018;119(11):9552-9559.
20. Sugimoto K, et al. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: a randomized, double-blind, multicenter study. J Crohns Colitis. 2020;14(12):1693-1701. PMID 32412598.
21. Ebrahimi Daryani N, et al. Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(2):2243-2255. PMID 40820062.

Share this:

×